News

AmorChem, UdeS Team Up to Advance Research of Natural Antibiotic Against Infections Linked to CF

The early-stage venture capital fund AmorChem has entered an agreement with Université de Sherbrooke (UdeS) and TransferTech Sherbrooke, in Canada, to optimize the antibiotic tomatidine for treating infections associated with cystic fibrosis (CF). Tomatidine is a naturally occurring product that can be extracted from tomatoes. Previous findings have…

Starting Kalydeco Treatment Before Birth May Help Halt CF Progression Post-Birth, Animal Study Suggests

Treating an animal model of cystic fibrosis (CF) with Kalydeco (ivacaftor) during embryonic development and after birth revealed that early treatment improved pancreatic function, delayed lung disease, and reduced infections, a study suggests. The study, titled “In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model…

Synspira’s CF Therapy Candidate SNSP113 Granted Orphan Drug Status in EU

Synspira Therapeutics’s candidate for treating cystic fibrosis, SNSP113, has received orphan drug designation from the European Medicines’ Agency (EMA) in the European Union. The status was granted by the EMA’s Committee for Orphan Medicinal Products (COMP), which reviews experimental treatments developed for rare diseases. Thick mucus accumulates…